Anxiety DisordersInterpersonal Functioning & Social ConnectednessMDMAMescaline

Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated

The paper explains the coining of the term "entactogen" for MDMA-like drugs, arguing they are distinct from classical hallucinogenic phenethylamines by three structural features (an N‑methylated nitrogen, a reversal of stereochemical potency, and tolerance of an alpha‑ethyl substitution) and by a unique psychopharmacology characterised by prosocial, anxiolytic and introspective effects. It further summarises the established mechanism for MDMA as uptake via the neuronal serotonin transporter followed by carrier‑mediated release of stored serotonin.

Authors

  • David Nichols

Published

Frontiers in Psychiatry
meta Study

Abstract

At first glance, it appears there is little difference between the molecular structures of methylenedioxymethamphetamine (MDMA), which has an N-methyl attached to its amino group, and methylenedioxyamphetamine (MDA), a primary amine that is recognized to have hallucinogenic activity. It is known from studies with other hallucinogenic amphetamines that N-methylation of hallucinogenic amphetamines attenuates or abolishes hallucinogenic activity. Nevertheless, MDMA is biologically active and has a potency only slightly less than its MDA parent. Importantly, it is the Ievo-isomer of hallucinogenic phenethylamines that is more biologically active, whereas it is the dextro isomer of MDMA that is more active. This reversal of stereochemistry for the activity of two very closely related molecules is a very powerful clue that their mechanisms of action differ. Finally, extension of the alpha-methyl of hallucinogenic amphetamines to an alpha-ethyl moiety completely abolishes their hallucinogenic activity. Ultimately, we extended the alpha-methyl group of MDMA to an alpha-ethyl to afford a molecule we named (N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB) that retained significant MDMA-like psychoactivity. Hence, there are three structural features that distinguish MDMA from the hallucinogenic amphetamines: (1) the N-methyl on the basic nitrogen, (2) the reversal of stereochemistry and, (3) tolerance of an alpha-ethyl moiety as contrasted with the alpha-methyl of hallucinogenic phenethylamines. Clearly, MDMA is distinct from classical hallucinogenic phenethylamines in its structure, and its psychopharmacology is also unique. Thus, in 1986 I proposed the name “Entactogen” for the pharmacological class of drugs that includes 3,4-methylenedioxymethamphetamine (MDMA) and other substances with a similar psychopharmacological effect. The name is derived from roots that indicate that entactogens produce a “touching within.” Rather than having significant psychostimulant, or hallucinogenic effects, MDMA powerfully promotes affiliative social behavior, has acute anxiolytic effects, and can lead to profound states of introspection and personal reflection. Its mechanism of action is now established as involving transport of MDMA by the neuronal serotonin reuptake carrier followed by carrier-mediated release of stored neuronal serotonin.

Available with Blossom Pro

Research Summary of 'Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated'

Introduction

By the mid-1980s MDMA had become widely used recreationally and was also reported, in anecdotal clinical settings, to produce striking therapeutic breakthroughs when given adjunctively in psychotherapy. At an Esalen conference the author encountered experienced therapists who described rapid retrieval of traumatic memories and sudden improvements in long-standing treatment stalemates following MDMA administration. Those reports, together with the prospect of imminent emergency scheduling of MDMA by the DEA as a ‘‘hallucinogenic amphetamine,’’ motivated an effort to examine whether MDMA’s pharmacology and structure were in fact distinct from classical psychedelic phenethylamines. This paper sets out to articulate the rationale for a new pharmacological class — entactogens — centred on MDMA and related compounds. Rather than presenting a systematic review, the article traces the structural, stereochemical, preclinical and early clinical evidence that informed the entactogen concept, and summarises later studies that validated key mechanistic and behavioural features relevant to therapy and social effects.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (6)

Papers cited by this study that are also in Blossom

MDMA enhances emotional empathy and prosocial behavior

´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)

Multifaceted empathy of healthy volunteers after single doses of MDMA: a pooled sample of placebo-controlled studies

Kuypers, K. P. C., Dolder, P. C., Ramaekers, J. G. et al. · Journal of Psychopharmacology (2017)

The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?

Bershad, A. K., Miller, M. A., Baggot, M. J. et al. · Journal of Psychopharmacology (2016)

Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.

Holze, F., Vizeli, P., Müller, F. et al. · Neuropsychopharmacology (2019)

214 cited
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)

Cited By (6)

Papers in Blossom that reference this study

Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Mitchell, J., Ot’alora G, M., van der Kolk, B. et al. · Nature Medicine (2023)

399 cited
Therapeutic mechanisms of psychedelics and entactogens

Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)

Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling

Henningfield, J. E., Coe, M. A., Griffiths, R. R. et al. · Neuropharmacology (2022)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.